U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H32Cl2N2O4
Molecular Weight 459.406
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LORGLUMIDE, (S)-

SMILES

CCCCCN(CCCCC)C(=O)[C@H](CCC(O)=O)NC(=O)C1=CC(Cl)=C(Cl)C=C1

InChI

InChIKey=IEKOTSCYBBDIJC-IBGZPJMESA-N
InChI=1S/C22H32Cl2N2O4/c1-3-5-7-13-26(14-8-6-4-2)22(30)19(11-12-20(27)28)25-21(29)16-9-10-17(23)18(24)15-16/h9-10,15,19H,3-8,11-14H2,1-2H3,(H,25,29)(H,27,28)/t19-/m0/s1

HIDE SMILES / InChI
Lorglumide (CR1409) is the first nonpeptidic, selective and potent inhibitor of the cholecystokinin-A and cholecystokinin-B receptors. Lorglumide prevented dose-dependently the emptying of the gallbladder in both experimental models; proglumide exhibited a comparable activity at much higher doses. Lorglumide was associated with significantly inhibited cell growth of human pancreatic cancer cell line Mia PaCa-2 in vitro. Lorglumide also induced G0/G1 cell cycle arrest and apoptosis. The change of invasion ability appeared to be mediated by MMP-2 expression, which was upregulated by CCK-8S and downregulated by lorglumide. Lorglumide had been in preclinical phase for the treatment of biliary dyskinesia, pancreatitis and cancer. However, this development was discontinued.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
4.9 µM [IC50]
PubMed

PubMed

TitleDatePubMed
Pharmacological characterization of a Chinese hamster ovary cell line transfected with the human CCK-B receptor gene.
1996 Aug
Postsynaptic Depolarization Enhances GABA Drive to Dorsomedial Hypothalamic Neurons through Somatodendritic Cholecystokinin Release.
2015 Sep 23
Peripheral apelin-13 administration inhibits gastrointestinal motor functions in rats: The role of cholecystokinin through CCK(1) receptor-mediated pathway.
2017 Jun
Intraperitoneal injection of nesfatin-1 primarily through the CCK-CCK1R signal pathway affects expression of appetite factors to inhibit the food intake of Siberian sturgeon (Acipenser baerii).
2018 Nov

Sample Use Guides

In Vivo Use Guide
Sources: Rats data
4 mg/kg was administered four times daily (at 6, 9, and 12 a.m. and 3 p.m.) for 14 days.
Route of Administration: Other
Name Type Language
LORGLUMIDE, (S)-
Common Name English
PENTANOIC ACID, 4-((3,4-DICHLOROBENZOYL)AMINO)-5-(DIPENTYLAMINO)-5-OXO-, (S)-
Systematic Name English
Code System Code Type Description
PUBCHEM
6604124
Created by admin on Sat Dec 16 10:30:23 UTC 2023 , Edited by admin on Sat Dec 16 10:30:23 UTC 2023
PRIMARY
CAS
118919-28-1
Created by admin on Sat Dec 16 10:30:23 UTC 2023 , Edited by admin on Sat Dec 16 10:30:23 UTC 2023
PRIMARY
FDA UNII
357WD8CT34
Created by admin on Sat Dec 16 10:30:23 UTC 2023 , Edited by admin on Sat Dec 16 10:30:23 UTC 2023
PRIMARY